Document Detail

Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
MedLine Citation:
PMID:  22415248     Owner:  NLM     Status:  Publisher    
PURPOSE: This study was conducted to evaluate relevant new information about ADRs reported in the Spanish paediatric population over a 6-year period. METHODS: Adverse drug reactions (ADRs) for individuals aged 0-17 years reported to the Spanish Pharmacovigilance System from 2004 to 2009 were analysed with respect to time, age and sex, category of ADR [System Organ Class (SOC)], seriousness, suspected medicines [level 2 of the Anatomical Therapeutic Chemical (ATC) Classification System] and type of reporter. RESULTS: In total, 4,279 ADR reports corresponding to 8,196 ADRs were analysed, approximately two ADRs per report. The rate of paediatric ADR reports in 2009 was 165 per million, of which nearly half (46 %) were for children (age group 2-11 years). Similar total numbers of ADRs were reported for boys and girls. The most frequent ADRs reported were from the following SOCs: general disorders and administration site conditions (34 %); skin and subcutaneous tissue disorders (15 %); nervous system disorders (14 %). Reports encompassed medicines from various ATC groups: vaccines and anti-infectives for systemic use (67 %); nervous system (9 %); respiratory system (9 %). On average, 37 % of ADRs were classified as serious. There were 33 fatal ADRs, and 35 % of the paediatric population associated with the ADR notifications required hospitalization or extended hospital stay. CONCLUSIONS: In Spain, ADR reporting rate in the paediatric population has increased since 2004. The proportion of suspected ADR reports related to vaccines was predominant, which highlights the important role played by nurses. ADR notification of congenital malformations in newborn infants highlights the need for joint action between the Spanish System of Pharmacovigilance of Medicines for Human Use (SEFV-H) and paediatricians, obstetricians and gynaecologists. The publication of safety reports by regulatory agencies is determinant for the increased number of ADR notifications.
A Aldea; M García Sánchez-Colomer; E Fernández Quintana; M García Sáiz
Related Documents :
16127478 - Ectopic eruption of a maxillary third molar tooth in the maxillary sinus: a case report.
6933858 - Mucogingival problems and the movement of mandibular incisors: a clinical review.
8617168 - Mandibular canine with two roots and three root canals.
12597678 - Occlusal guidance for eruption disturbance of mandibular second premolar: a report of t...
874068 - Hypercalcemic hyperparathyroidism in hypophosphatemic rickets.
8630988 - Dicentric (1;15) in myeloid disorders.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-14
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  -     ISSN:  1432-1041     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Unidad Central de Investigación Clínica y Ensayos Clínicos, Hospital Universitario de Canarias, Ofra, s/n. La Cuesta, 38320, San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic screening for chromosomal abnormalities and Y chromosome microdeletions in Chinese infertile...
Next Document:  On the definition and the computation of the type-reproduction number T for structured populations i...